Senseonics (NYSE:SENS) Shares Gap Up – Still a Buy?

Senseonics Holdings, Inc. (NYSE:SENS)’s stock price gapped up before the market opened on Thursday . The stock had previously closed at $1.17, but opened at $1.23. Senseonics shares last traded at $1.29, with a volume of 5,848,861 shares traded.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on SENS shares. HC Wainwright reaffirmed a “buy” rating and set a $2.00 target price on shares of Senseonics in a research report on Friday, November 15th. StockNews.com started coverage on Senseonics in a research report on Thursday, December 26th. They issued a “sell” rating for the company.

Senseonics Price Performance

The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The business has a 50 day simple moving average of $0.73 and a 200-day simple moving average of $0.48.

Insider Transactions at Senseonics

In related news, CEO Timothy T. Goodnow purchased 315,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were bought at an average price of $0.31 per share, with a total value of $97,650.00. Following the acquisition, the chief executive officer now owns 11,310,355 shares of the company’s stock, valued at $3,506,210.05. This trade represents a 2.86 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Frederick T. Sullivan purchased 124,933 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the acquisition, the chief financial officer now directly owns 2,478,844 shares in the company, valued at $941,960.72. This trade represents a 5.31 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Senseonics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. bought a new stake in Senseonics during the 4th quarter valued at $26,000. HighTower Advisors LLC bought a new position in shares of Senseonics in the fourth quarter worth $32,000. Ridgecrest Wealth Partners LLC bought a new position in shares of Senseonics in the fourth quarter worth $60,000. Northern Trust Corp increased its holdings in shares of Senseonics by 11.2% in the fourth quarter. Northern Trust Corp now owns 1,194,960 shares of the company’s stock worth $625,000 after purchasing an additional 120,441 shares during the period. Finally, Beck Mack & Oliver LLC bought a new position in shares of Senseonics in the fourth quarter worth $79,000. Institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.